ACUR · Acura Pharmaceuticals, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $1.56M | $3.57M | $2.66M | $410.0K | $2.97M | $4.46M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $1.52M | $1.78M | $1.50M | $1.76M | $3.72M | $4.03M |
| SG&A | $1.25M | $2.55M | $1.88M | $2.57M | $4.34M | $6.52M |
| Total Operating Expenses | $2.78M | $4.33M | $3.38M | $4.33M | $8.19M | $11.02M |
| D&A | $47.0K | $56.0K | $66.0K | $73.0K | $87.0K | $138.0K |
| Operating Income | ($1.21M) | ($758.0K) | ($725.0K) | ($3.92M) | ($5.22M) | ($6.56M) |
| Interest Expense | $200.0K | $450.0K | $449.0K | $223.0K | $596.0K | $893.0K |
| Income Tax | $0 | $0 | $0 | $0 | ($135.0K) | $0 |
| Net Income | ($879.0K) | ($1.21M) | ($3.77M) | ($3.84M) | ($5.68M) | ($7.39M) |
| EPS - Basic | ($0.02) | ($0.04) | ($0.14) | ($0.18) | ($0.36) | ($0.62) |
| EPS - Diluted | ($0.02) | ($0.04) | ($0.14) | ($0.18) | ($0.36) | ($0.62) |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $65.0K | $413.0K | $862.0K | $91.0K | $2.22M | $2.68M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | $0 | $309.0K |
| Accounts Payable | $192.0K | $31.0K | $237.0K | $605.0K | $3.0K | $77.0K |
| Current Assets | $372.0K | $1.18M | $1.18M | $461.0K | $2.57M | $5.91M |
| Total Assets | $860.0K | $1.74M | $2.56M | $2.15M | $4.60M | $8.21M |
| Current Liabilities | $515.0K | $7.52M | $1.07M | $1.44M | $4.63M | $3.49M |
| Long-term Debt | - | - | $6.00M | $4.22M | $0 | $2.98M |
| Total Liabilities | $682.0K | $7.63M | $7.30M | $5.77M | $4.63M | $7.03M |
| Stockholders' Equity | $178.0K | ($5.89M) | ($4.74M) | ($3.62M) | ($27.0K) | $1.18M |
| Retained Earnings | ($390.08M) | ($389.20M) | ($388.00M) | ($384.22M) | ($380.38M) | ($374.70M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($742.0K) | ($719.0K) | ($618.0K) | ($3.91M) | ($5.56M) | ($5.56M) |
| Investing Cash Flow | - | - | - | $0 | $10.80M | $10.80M |
| Financing Cash Flow | $394.0K | $270.0K | $1.39M | $1.78M | ($2.54M) | ($2.54M) |
| CapEx | - | - | - | - | $0 | $75.0K |
| Free Cash Flow | - | - | - | - | ($5.56M) | ($5.64M) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -77.7% | -21.2% | -27.3% | -954.9% | -176.2% | -146.9% |
| EBITDA margin | -74.7% | -19.7% | -24.8% | -937.1% | -173.2% | -143.8% |
| Net margin | -56.2% | -33.8% | -142.0% | -937.1% | -191.6% | -165.5% |
| Free cash flow margin | - | - | - | - | -187.6% | -126.3% |
| FCF / Net income | - | - | - | - | 0.98 | 0.76 |
| R&D / Revenue | 97.5% | 49.9% | 56.6% | 429.0% | 125.5% | 90.2% |
| SG&A / Revenue | 80.2% | 71.3% | 70.6% | 625.9% | 146.4% | 146.0% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -102.2% | -69.6% | -147.3% | -178.5% | -123.4% | -90.0% |
| Return on equity | -493.8% | 20.5% | 79.6% | 106.2% | 21044.4% | -624.5% |
| Return on invested capital | - | - | -45.5% | -509.5% | - | -124.5% |
| Liquidity | ||||||
| Current ratio | 0.72 | 0.16 | 1.10 | 0.32 | 0.55 | 1.69 |
| Quick ratio | 0.72 | 0.16 | 1.10 | 0.32 | 0.55 | 1.61 |
| Cash ratio | 0.13 | 0.05 | 0.80 | 0.06 | 0.48 | 0.77 |
| Leverage | ||||||
| Debt / Equity | - | - | -1.27 | -1.17 | 0.00 | 2.52 |
| Debt / Assets | - | - | 2.34 | 1.96 | 0.00 | 0.36 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -6.1x | -1.7x | -1.6x | -17.6x | -8.8x | -7.3x |
| Equity multiplier | 4.83 | -0.29 | -0.54 | -0.59 | -170.52 | 6.94 |
| Liabilities / Assets | 0.79 | 4.39 | 2.85 | 2.68 | 1.01 | 0.86 |
| Efficiency | ||||||
| Asset turnover | 1.82 | 2.06 | 1.04 | 0.19 | 0.64 | 0.54 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -56.2% | 34.4% | 548.0% | -86.2% | -33.6% | -48.0% |
| Revenue CAGR (3y) | 56.2% | 6.4% | -15.9% | -63.7% | 58.1% | 231.1% |
| Revenue CAGR (5y) | -18.9% | -16.1% | 28.8% | 27.2% | - | 3.1% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -60.2% | -4.6% | 81.5% | 25.1% | 20.3% | -63.9% |
| Net income growth (YoY) | 27.2% | 68.0% | 1.8% | 32.4% | 23.1% | -48.1% |
| EPS growth (YoY) | 50.0% | 71.4% | 22.2% | 50.0% | 41.9% | -34.8% |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | 1.3% | -44.5% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | -24.3% | -31.1% | -13296.3% | - | -85.0% |
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
-386.77
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ACURA PHARMACEUTICALS against the 5 most active filers in the same SIC group.